MERCK & CO., INC. (MRK)
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
BONDS 1 - semi-annual weighted interest rate that will be paid on 30.6.26
Range Declares Quarterly Dividend
OUE Healthcare Limited - Announcement
Compagnie du Cambodge : Modalités de mise à disposition des informations relatives à l’Assemblée générale ordinaire des actionnaires du vendredi 19 juin 2026
Natuzzi Announces Resignation of a Board Member, Pietro Labriola
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Prosafe SE: Annual General Meeting completed
Natera - Natera Announces Collaboration with Diakonos Oncology forSignatera™ in Refractory Melanoma
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)